Evogene Revenue vs. Shares Owned By Insiders
| EVGN Stock | ILA 583.60 16.20 2.70% |
For Evogene profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Evogene to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Evogene utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Evogene's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Evogene over time as well as its relative position and ranking within its peers.
Evogene |
Evogene Shares Owned By Insiders vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Evogene's current stock value. Our valuation model uses many indicators to compare Evogene value to that of its competitors to determine the firm's financial worth. Evogene is rated # 3 in revenue category among its peers. It also is rated # 3 in shares owned by insiders category among its peers . The ratio of Revenue to Shares Owned By Insiders for Evogene is about 259,777 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Evogene by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Evogene's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Evogene Revenue vs. Competition
Evogene is rated # 3 in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 116.21 Million. Evogene maintains roughly 930,000 in revenue contributing less than 1% to equities under Health Care industry.
Evogene Shares Owned By Insiders vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Evogene |
| = | 930 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Evogene |
| = | 3.58 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Evogene Shares Owned By Insiders Comparison
Evogene is currently under evaluation in shares owned by insiders category among its peers.
Evogene Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Evogene, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Evogene will eventually generate negative long term returns. The profitability progress is the general direction of Evogene's change in net profit over the period of time. It can combine multiple indicators of Evogene, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. EVOGENE operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 131 people.
Evogene Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Evogene. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Evogene position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Evogene's important profitability drivers and their relationship over time.
Use Evogene in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.Evogene Pair Trading
Evogene Pair Trading Analysis
The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.
The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Evogene position
In addition to having Evogene in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alternative Energy Thematic Idea Now
Alternative Energy
Large and mid-size companies, ETFs and funds that are either investing or directly involved in providing energy derived from sources not connected to fossil fuels, do not consume natural resources, and do not harm the environment. This includes wind power, nuclear and solar energy, biofuel, ethanol, hydrogen and others alternative sources of energy. The Alternative Energy theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alternative Energy Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Evogene Stock
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:Check out Investing Opportunities. For information on how to trade Evogene Stock refer to our How to Trade Evogene Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
To fully project Evogene's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Evogene at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Evogene's income statement, its balance sheet, and the statement of cash flows.